Coherus Oncology (CHRS) EPS (Basic) (QoQ) (2013 - 2026)
Coherus Oncology (CHRS) EPS (Basic) (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - |
| 10 | Coherus Oncology | 215.97 Mn | 110.66 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 904.83% |
| Mar 31, 2026 | -113.74% |
| Dec 31, 2025 | -3.89% |
| Sep 30, 2025 | -97.38% |
| Jun 30, 2025 | 3,828.93% |
| Mar 31, 2025 | -97.00% |
| Dec 31, 2024 | -112.56% |
| Sep 30, 2024 | -12.42% |
| Jun 30, 2024 | -75.91% |
| Mar 31, 2024 | 279.20% |
| Dec 31, 2023 | -108.57% |
| Sep 30, 2023 | 17.43% |
| Jun 30, 2023 | 48.58% |
| Mar 31, 2023 | -25.98% |
| Dec 31, 2022 | 31.96% |
| Sep 30, 2022 | -72.35% |
| Jun 30, 2022 | 48.01% |
| Mar 31, 2022 | -105.42% |
| Dec 31, 2021 | -24.17% |
| Sep 30, 2021 | -23.22% |